Navigation Links
Handa Pharmaceuticals Announces Submission of its First-to-File ANDA for AstraZeneca's SEROQUEL(R) XR
Date:7/31/2008

FREMONT, Calif., July 31 /PRNewswire/ -- Handa Pharmaceuticals, LLC ("Handa"), a specialty pharmaceutical company based in Fremont, California, today confirmed that its Abbreviated New Drug Application ("ANDA") for Quetiapine Fumarate Extended-Release Tablets, the generic version of AstraZeneca's SEROQUEL(R) XR, has been accepted for filing by the U.S. Food and Drug Administration ("FDA"). Based upon available information, Handa believes that it is the first applicant to file an ANDA for SEROQUEL(R) XR containing a Paragraph IV certification, under the provisions of the Hatch- Waxman Act. Should its ANDA be approved by the FDA, Handa believes that its product will be entitled to 180 days of generic market exclusivity.

About Handa Pharmaceuticals, LLC

Handa Pharmaceuticals, LLC is a specialty pharmaceutical company that was established in the San Francisco Bay area in November 2005. Handa's executive leadership has a proven track record of developing controlled-release prescription pharmaceutical products that are difficult to formulate. For more information, please visit http://www.handapharma.com.

Forward-Looking Statements

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Handa's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Handa disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Handa's current expectations depending upon a number of factors affecting Handa's business. These factors include, among others, patents and other intellectual property rights held by competitors and other third parties and the uncertainty of the outcome of litigation related to such patents and intellectual property rights; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; the impact of competitive products and pricing; market acceptance of and demand for Handa's products; difficulties or delays in manufacturing; and other risks and uncertainties.

SEROQUEL(R) and SEROQUEL(R) XR are registered trademarks of the AstraZeneca group of companies.

Contact: Stephen Cary of Handa Pharmaceuticals, LLC, +1-510-354-2888


'/>"/>
SOURCE Handa Pharmaceuticals, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
2. Trubion Pharmaceuticals Provides Announcement Dates for Second Quarter and First Six Months Earnings Conference Call
3. DoctorDirectory to Co-market VoSpire ER(R) with DAVA Pharmaceuticals, Inc.
4. Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
5. Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP
6. New Natural Product from Zurich Pharmaceuticals Downs Appetite
7. AUDIO from Medialink and Duramed Pharmaceuticals: Not Your Mothers Menopause
8. Genesis Pharmaceuticals Announces New Board Member and Forms Committees
9. Sound Pharmaceuticals Receives Additional DoD Funding for Its Hearing Regeneration Product
10. AUDIO from Medialink and Duramed Pharmaceuticals: Relief for Women Experiencing Surgical Menopause
11. Genesis Pharmaceuticals Announces SFDA Approval for Radix Isatidis Dispersible Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... and surrounding areas with a vital new community enrichment program, has teamed up with ... local women and children suffering from intimate abuse. To support all those victimized by ...
(Date:2/8/2016)... ... 2016 , ... Delta Dental of California and its affiliated companies announced today ... Radine, who recently retired as president and CEO of Delta Dental of California and ... the Year , helped lead the effort to raise funds for studies to strengthen ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and ... number of women and men with eating disorders report a history of trauma, ... the development of an eating disorder. , At the 2016 iaedp Symposium, ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially ... to make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... will be speaking on how healthcare companies can use newly released government data ... health of a population and intervene and capture the value they create to ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... France , Germany , ... Israel ). It includes a 10-year epidemiology forecast for the total ... and sex in these markets. GD epidemiology report is written and developed ... transparent and market-driven, providing expert analysis of disease trends in the 7MM. ... Italy , Spain , UK, and ...
(Date:2/4/2016)... Ohio , Feb. 4, 2016 For ... Program, or those already participating in the program, the ... often referred to as the , Mega-Guidance , could ... final guidance is published in September 2016. ... Product and Service Marketing , summarizes the Mega-Guidance,s key ...
(Date:2/4/2016)... -- The Senior Care Pharmacy Coalition (SCPC) today commended ... Jason Chaffetz (R-UT) and Ranking Member Elijah ... "Developments in the Prescription Drug Market," to examine ... abusive pharmacy benefit manager (PBM) pricing practices. ... Elijah Cummings (D-MD) are diligent, serious lawmakers committed ...
Breaking Medicine Technology: